Impax Laboratories — J.P. Morgan Healthcare Conference 2014
22 slides from Impax Laboratories's conference presentation, Jan 14, 2014

Slide 1: J.P. Morgan Healthcare Conference
DEX J.P. Morgan Healthcare Conference IPXL NANDA January 14, 2014 LISTED

Slide 2: Agenda
\o/ 8 * Impax Overview * Our Growth Strategy * Quality and Operations * Generic Business « Branded Business * 2014 Financial Outlook

Slide 3: Forward-Looking Statement
Forward-Looking Statement “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward- looking in nature and express the beliefs and expectations of

Slide 4: Leveraging Our Dual Business Model
Leveraging Our Dual Business Model @/s Generic Dd) |) IM Ces IN Shared Services QD IMPAX

Slide 5: Investments Drove Revenue Growth...
Investments Drove Revenue Growth... Created Significant Resources to Fund Business Development and M&A 27% 6-Year CAGR $683 $573 2006 2007 2008 2009 2010 2011 2012 $ milions, Annual revenues as reported (GAAP) except: 12010 which excludes $196MM due to @ change in revenue recognition under the Teva

Slide 6: ..And High Margin Opportunities
..And High Margin Opportunities Continuing to Target High Value Generic Products and Building a Brand Pipeline Last Twelve Months Adjusted Results as of September 2013 Gross Margin R&D as a % of Sales 13% 67% 59% 58% 55% 53% 8% 8% 8% 7% 7% T% g 4 A SPE ELKES 5 source: Company quarter earings release

Slide 7: Strategy to Create Long-Term Growth
Strategy to Create Term Growth @ /A REVENUE GROWTH OPPORTUNITIES Internal High Value R&D Opportunities External High Value R&D Through Partnerships Business Development QD IMPAX

Slide 8: Business Development/M&A Objectives
Generics specific Business Development/M&A Objectives High value Solid Oral Dose or Alternative Dosage Form product opportunities Companies with R&D capability (US or ex-US) Brand specific Products for neurologists or psychiatrists Neurology or psychiatry focused pipeline product(s) with near-term l

Slide 9: A Strategic Approach to Operations
A Strategic Approach to Operations IT/Finance }| Compliance Manufacturing

Slide 10: Generic Business
Generic Business < tf Unique Targeted ANDAs First-to-File/First-to-Market Sustainable Products Strategic Partnerships/M&A

Slide 11: 2013 Generic Product Launches
2013 Generic Product Launches January Oxymorphone Hydrochloride ER tablets (First-to-File) May Authorized generic Zomig® tablets Authorized generic Zomig® Orally Disintegrating Tablets July Authorized generic Trilipix® Delayed Release Capsules November Solaraze® Gel 3% (First-to-File) "

Slide 12: Diversifying Currently Marketed Portfolio
Diversifying Currently Marketed Portfolio 47 Currently Marketed Products Alternative Controlled-Release Dosage Form 10 13 Solid Oral 21% 28% Other Solid Oral 51% Note: Data as of December 2013 QD IMPAX 12

Slide 13: Diversifying Generic Product Pipeline
Diversifying Generic Product Pipeline 77 Future Opportunities Pending at FDA or Under Development $26B Current U.S. Brand/Generic Sales M1 36 4 J | # 14 14 Pending at FDA Under Development 18 Total ADF 37 Total C-R SOD 22 Total Other SOD 23% of Pipeline 48% of Pipeline 29% of Pipeline Note: Date as

Slide 14: Brand Business
Brand Business < tf Creating CNS Products "Y RYTARY™ Pending NDA Approval Commercializing Zomig® in US Strategic Partnerships/M&A

Slide 15: RYTARY (IPX066) for Parkinson's Disease
RYTARY™ (IPX066): Carbidopa and Levodopa Extended-Release Capsule for the Symptomatic Treatment of Parkinson’s Disease Jan. 21 2013°) 2014 Targeting NDA resubmission pending FDA confirmation that Hayward inspection deficiencies are resolved PDUFA Date - Received Complete Response Letter More than on

Slide 16: Continuing Our Commercial Success
Continuing Our Commercial Success o Tablet and ZMT patents expired May 2013 = Continuing commercialization of Zomig® Nasal Spray o Nasal Spray patent expires May 2021 Building relationships with neurologists since July 2006 = Began commercializing Zomig® in April 2012 Nasal Triptan Category Share, N

Slide 17: Building a Branded Product Pipeline
Building a Branded Product Pipeline PROJECT | INDICATION | PHASE! | PHASE | PHASE | REGISTRATION | APPROVED or POC i] Ill Zomig® Migraine Zolmitriptan RYTARY™ Parkinson’s /IPXO66@) Disease Carbidopa-Levodopa (CD-LD) ELADUR@/ Postherpetic IPX239 Neuralgia Bupivacaine (PHN) Several IPXe. Early Stage P

Slide 18: ELADUR - Bupivacaine Patch for PHN
ELADUR® - Bupivacaine Patch for PHN ELADUR®: In-licensed from DURECT Corporation + Postherpetic neuralgia (PHN) fits within specialty CNS strategy + ) * Orphan drug designation — 7 year orphan exclusivity bia + Impax will control and fund development program Targeted Product Profile + Potential dura

Slide 19: 2014 Financial Outlook
Impax Laboratories < tf " = _ ~~ _ a 2014 Financial Outlook

Slide 20: 2014 Objectives
20 2014 Objectives Complete implementation of a best in class “Quality Improvement Program” in line with our “Quality First Culture” RYTARY™ * NDA resubmission « File European “Market Authorization Application” by 2H 2014 * Out-license ex-US Successfully commercialize potential new generic product l

Slide 21: 2014 Financial Outlook
2014 Financial Outlook Forecast Range Adjusted gross margin") Low 50% range Expenses ($ in millions) Total research and development (R&D) $82 to $88 Generic R&D $46 to $49 Brand R&D $36 to $39 Patent litigation $11 to $13 Selling, general and administrative $115 to $120 Other items ($ in millions) T

Slide 22: Positioned for Future Growth
Positioned for Future Growth Targeting Sustainable Generic and Specialized Brand Markets Established Core Competencies Strong and Flexible Financial Profile Generic pipeline targeting $26B U.S. sales Brand pipeline focused on Central Nervous System (CNS) Solid platform on which to build long-term gr
Source: SEC EDGAR · 8-K filed Jan 14, 2014
More decks from Impax Laboratories Inc
Q4 2017 Earnings Presentation23 slides · Mar 1, 2018
J.P. Morgan Global Healthcare Conference 201819 slides · Jan 9, 2018
Q3 2017 Earnings Presentation22 slides · Nov 9, 2017
Merger or Acquisition (October 2017)22 slides · Oct 17, 2017
Merger or Acquisition (October 2017)43 slides · Oct 17, 2017
Q2 2017 Earnings Presentation24 slides · Aug 9, 2017